Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there?
When Novartis reported first-half Zolgensma sales a few months ago, the company said its spinal muscular atrophy gene therapy was growing thanks to "expanding access" in Europe. This week at the Fierce Biotech Cell & Gene Therapy event, an exec outlined what's driving the uptake.
Source: fiercepharma.com